Benzinga | Nov 4, 2021 09:23AM EDT

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data From Lead PBCAR0191 CAR T Immunotherapy For Relapsed And Refractory B-cell Malignancies At The 63rd Annual Meeting Of The American Society Of Hematology

- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines of Therapy

- Clinically Significant Activity in Subjects Previously Treated with Autologous CD19 Directed CAR T

- In B-ALL Subjects Enhanced Lymphodepletion or Higher Doses of PBCAR0191 Resulted in High Complete Response Rates Allowing the Potential to Bridge to Allogeneic Stem Cell Transplant

- Data Presented at ASH will be Updated to Include Subjects with >28 Day Follow up as of October 10, 2021